Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shorla Oncology

Request full access

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers.

Cloghjordan, IrelandFounded 2018Biotech & Life Sciences

About Shorla Oncology

At Shorla Oncology we develop and commercialize innovative oncology drugs. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments.

Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.

Source: Dealroom company data

At a glance

Status
Operational
Employees
45
Open positions
None listed
Dealroom signal
67.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Medical Research, Oncology, Medical & Healthcare, Patient Engagement, Tech for Patients, Biotech and Pharma, biotech medtech and e-health, Woman Founder, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
FundingOther financing Jan 2026 $20M — Undisclosed ↗
SERIES BOther financing Sep 2025 — — Enterprise Ireland —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Shorla Oncology website traffic

Latest recorded traffic for Shorla Oncology is 100 monthly website visits, down 33.3% over the last three months. Shorla Oncology's team grew 4.7% over the past year.

Latest monthly visits100 3-month web change-33.3% 1-year team growth+4.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shorla Oncology in the Cloghjordan ecosystem

Live from Dealroom

The Shorla Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Seroba Life Sciences
  • Enterprise Ireland
  • Kurma Partners
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇮🇪 Ireland57.5%
🇺🇸 United States37.5%
🇬🇧 United Kingdom5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shorla Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shorla Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.